United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News Harmony Biosciences faces FDA setback for pitolisant in idiopathic hypersomnia Harmony Biosciences Holdings, Inc. has encountered a regulatory hurdle in its efforts to expand the use of pitolisant… byPallavi MadhirajuFebruary 20, 2025